For example, in NSCLC patients resistant to first-generation EGFR TKIs, the incidence of MET gene amplification is 5%-22% (41, 60–67), while in patients resistant to third-generation EGFR TKIs, the incidence of MET gene amplification can be as high as 10%-26% (69, 72–75); in NSCLC patients resistant to second-generation ALK TKIs, the incidence of MET gene amplification is approximately 12%, whereas in patients resistant to third-generation ALK TKIs, MET gene amplification can reach 22% (76). Here, MET is linked to non-small cell lung carcinoma.